Most common side effect for both peptides
If GLP-1 receptor agonism, and by extension the dual and triple agonists, and possibly the cleaner endogenous peptides like BRP, operates as a class of geroscience interventions rather than a class of weight-loss drugs that happen to have nice cardiovascular side benefits, then the population for whom these molecules might matter is much larger than the population that currently qualifies for them under any obesity- or diabetes-based prescribing guideline
All the similar weight loss apps I came across work off the same exact model
Opportunity costs: Time researching vendors, verifying quality, troubleshooting problems, or dealing with poor customer service creates hidden costs
That said, functional medicine thrives on looking at early evidence, asking good questions, and integrating therapies when benefits may outweigh risks
Store upright in your refrigerator away from strong odors